Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Immunotherapy for Peanut Allergy
NCT00580606Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2007
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peanut allergy comparing Low Dose Peanut SLIT with Placebo -> High Dose Peanut SLIT (2 arms). Primary endpoint: Percent of Participants Who Successfully Consumed 5,000 mg of Peanut Powder or at Least a 10-fold Increase in the Amount of Peanut Powder Compared to Their Baseline Oral Food Challenge at Week 44. Started Dec 2007; status: completed.
02
Drugs
peanut allergen extract
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT00580606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00580606.